Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (TLX) Stock Overview

Explore Telix Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.

TLX●NASDAQ
HealthcareBiotechnology
$11.33
$1.09(8.78%)
U.S. Market opens in 62h 58m

Telix Pharmaceuticals Limited (TLX)

Meyka AI Score

Z

Key Financials

Market Cap3.8B
P/E Ratio-497.57
EPS (TTM)$-0.02
ROE-0.02%
Fundamental Analysis

AI Price Forecasts

1 Month$10.14
3 Months$8.45
1 Year Target$4.82

TLX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Telix Pharmaceuticals Limited (NASDAQ: TLX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Telix Pharmaceuticals Limited's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of TLX on the NASDAQ shows an RSI of 50.85, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $4.82 for the NASDAQ listing.

Key metrics behind Telix Pharmaceuticals Limited's NASDAQ-traded stock include a P/E ratio of -497.57 and a market capitalization of 3.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of TLX on the NASDAQ.

Price Performance (NASDAQ: TLX)

1-Day Change
-8.78%
5-Day Change
-5.27%
1-Month Change
3.75%
3-Month Change
10.32%
6-Month Change
47.33%
Year-to-Date (YTD) Change
51.27%
1-Year Change
-6.29%
3-Year Change
-25.21%
5-Year Change
-25.21%
All-Time (Max) Change
-25.21%

Contact Information

https://telixpharma.com
61 3 9093 3855
55 Flemington Road, North Melbourne, VIC, 3051

Company Facts

11,520 Employees
IPO DateNov 14, 2024
CountryAU
Actively Trading

Frequently Asked Questions